Literature DB >> 17449633

Interleukin 31 mediates MAP kinase and STAT1/3 activation in intestinal epithelial cells and its expression is upregulated in inflammatory bowel disease.

Julia Dambacher1, Florian Beigel, Julia Seiderer, Dirk Haller, Burkhard Göke, Christoph J Auernhammer, Stephan Brand.   

Abstract

BACKGROUND/AIM: Interleukin 31 (IL31), primarily expressed in activated lymphocytes, signals through a heterodimeric receptor complex consisting of the IL31 receptor alpha (IL31Ralpha) and the oncostatin M receptor (OSMR). The aim of this study was to analyse IL31 receptor expression, signal transduction, and specific biological functions of this cytokine system in intestinal inflammation.
METHODS: Expression studies were performed by RT-PCR, quantitative PCR, western blotting, and immunohistochemistry. Signal transduction was analysed by western blotting. Cell proliferation was measured by MTS assays, cell migration by restitution assays.
RESULTS: Colorectal cancer derived intestinal epithelial cell (IEC) lines express both IL31 receptor subunits, while their expression in unstimulated primary murine IEC was low. LPS and the proinflammatory cytokines TNF-alpha, IL1beta, IFN-gamma, and sodium butyrate stimulation increased IL31, IL31Ralpha, and OSMR mRNA expression, while IL31 itself enhanced IL8 expression in IEC. IL31 mediates ERK-1/2, Akt, STAT1, and STAT3 activation in IEC resulting in enhanced IEC migration. However, at low cell density, IL31 had significant antiproliferative capacities (p<0.005). IL31 mRNA expression was not increased in the TNFDeltaARE mouse model of ileitis but in inflamed colonic lesions compared to non-inflamed tissue in patients with Crohn's disease (CD; average 2.4-fold increase) and in patients with ulcerative colitis (UC; average 2.6-fold increase) and correlated with the IL-8 expression in these lesions (r = 0.564 for CD; r = 0.650 for UC; total number of biopsies analysed: n = 88).
CONCLUSION: IEC express the functional IL31 receptor complex. IL31 modulates cell proliferation and migration suggesting a role in the regulation of intestinal barrier function particularly in intestinal inflammation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17449633      PMCID: PMC1954980          DOI: 10.1136/gut.2006.118679

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  57 in total

1.  Fractalkine is an epithelial and endothelial cell-derived chemoattractant for intraepithelial lymphocytes in the small intestinal mucosa.

Authors:  A Muehlhoefer; L J Saubermann; X Gu; K Luedtke-Heckenkamp; R Xavier; R S Blumberg; D K Podolsky; R P MacDermott; H C Reinecker
Journal:  J Immunol       Date:  2000-03-15       Impact factor: 5.422

2.  IL-23: a master regulator in Crohn disease.

Authors:  Markus F Neurath
Journal:  Nat Med       Date:  2007-01       Impact factor: 53.440

3.  Molecular and functional characterization of a soluble form of oncostatin M/interleukin-31 shared receptor.

Authors:  Caroline Diveu; Emilie Venereau; Josy Froger; Elisa Ravon; Linda Grimaud; François Rousseau; Sylvie Chevalier; Hugues Gascan
Journal:  J Biol Chem       Date:  2006-10-06       Impact factor: 5.157

Review 4.  Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis.

Authors:  R Balfour Sartor
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2006-07

5.  Interleukin-31 and oncostatin-M mediate distinct signaling reactions and response patterns in lung epithelial cells.

Authors:  Souvik Chattopadhyay; Erin Tracy; Ping Liang; Olivier Robledo; Stefan Rose-John; Heinz Baumann
Journal:  J Biol Chem       Date:  2006-12-05       Impact factor: 5.157

6.  BMP-7-induced cell cycle arrest of anaplastic thyroid carcinoma cells via p21(CIP1) and p27(KIP1).

Authors:  N E Heldin
Journal:  Biochem Biophys Res Commun       Date:  2001-07-20       Impact factor: 3.575

7.  Cell density-dependent proliferative effects of transforming growth factor (TGF)-beta 1, beta 2, and beta 3 in human chondrosarcoma cells HCS-2/8 are associated with changes in the expression of TGF-beta receptor type I.

Authors:  K Boumédiene; M Takigawa; J P Pujol
Journal:  Cancer Invest       Date:  2001       Impact factor: 2.176

8.  Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells.

Authors:  R Garcia; T L Bowman; G Niu; H Yu; S Minton; C A Muro-Cacho; C E Cox; R Falcone; R Fairclough; S Parsons; A Laudano; A Gazit; A Levitzki; A Kraker; R Jove
Journal:  Oncogene       Date:  2001-05-03       Impact factor: 9.867

9.  Novel interferon-lambdas induce antiproliferative effects in neuroendocrine tumor cells.

Authors:  Kathrin Zitzmann; Stephan Brand; Sebastian Baehs; Burkhard Göke; Jennifer Meinecke; Gerald Spöttl; Heinrich Meyer; Christoph J Auernhammer
Journal:  Biochem Biophys Res Commun       Date:  2006-04-24       Impact factor: 3.575

10.  IL-31-IL-31R interactions negatively regulate type 2 inflammation in the lung.

Authors:  Jacqueline G Perrigoue; Ji Li; Colby Zaph; Michael Goldschmidt; Phillip Scott; Frederic J de Sauvage; Edward J Pearce; Nico Ghilardi; David Artis
Journal:  J Exp Med       Date:  2007-03-12       Impact factor: 14.307

View more
  42 in total

1.  Chemotherapy-induced intestinal inflammatory responses are mediated by exosome secretion of double-strand DNA via AIM2 inflammasome activation.

Authors:  Qiaoshi Lian; Jun Xu; Shanshan Yan; Min Huang; Honghua Ding; Xiaoyu Sun; Aiwei Bi; Jian Ding; Bing Sun; Meiyu Geng
Journal:  Cell Res       Date:  2017-04-14       Impact factor: 25.617

2.  Methylation and microRNA-mediated epigenetic regulation of SOCS3.

Authors:  Chandra S Boosani; Devendra K Agrawal
Journal:  Mol Biol Rep       Date:  2015-04       Impact factor: 2.316

3.  Feline Interleukin-31 Shares Overlapping Epitopes with the Oncostatin M Receptor and IL-31RA.

Authors:  Angelica V Medina-Cucurella; Gary F Bammert; William Dunkle; Christopher Javens; Yaqi Zhu; Veronica T Mutchler; Janet T Teel; Caitlin A Stein; Steve A Dunham; Timothy A Whitehead
Journal:  Biochemistry       Date:  2020-06-04       Impact factor: 3.162

4.  Bisphenol-A alters microbiota metabolites derived from aromatic amino acids and worsens disease activity during colitis.

Authors:  Jennifer Aa DeLuca; Kimberly F Allred; Rani Menon; Rebekah Riordan; Brad R Weeks; Arul Jayaraman; Clinton D Allred
Journal:  Exp Biol Med (Maywood)       Date:  2018-06-06

5.  Delineating the signals by which repetitive deformation stimulates intestinal epithelial migration across fibronectin.

Authors:  Christopher P Gayer; Lakshmi S Chaturvedi; Shouye Wang; Brittany Alston; Thomas L Flanigan; Marc D Basson
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-01-29       Impact factor: 4.052

6.  Correlation of IL-31 gene polymorphisms with susceptibility and clinical recurrence of bladder cancer.

Authors:  Qin Li; Tielong Tang; Peng Zhang; Chenlu Liu; Yan Pu; Yan Zhang; Huizi Song; Yanyun Wang; Yaping Song; Min Su; Bin Zhou; Lin Zhang
Journal:  Fam Cancer       Date:  2018-10       Impact factor: 2.375

7.  Molecular dissection of human interleukin-31-mediated signal transduction through site-directed mutagenesis.

Authors:  Sabine Le Saux; François Rousseau; Fabien Barbier; Elisa Ravon; Linda Grimaud; Yannic Danger; Josy Froger; Sylvie Chevalier; Hugues Gascan
Journal:  J Biol Chem       Date:  2009-11-17       Impact factor: 5.157

8.  Role of IL-31 in regulation of Th2 cytokine levels in patients with nasal polyps.

Authors:  Hong Ouyang; Jie Cheng; Yajun Zheng; Jingdong Du
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-02-11       Impact factor: 2.503

Review 9.  Structures and biological functions of IL-31 and IL-31 receptors.

Authors:  Qing Zhang; Prabhakar Putheti; Qiang Zhou; Quansheng Liu; Wenda Gao
Journal:  Cytokine Growth Factor Rev       Date:  2008-10-15       Impact factor: 7.638

10.  Simultaneous profiling of 194 distinct receptor transcripts in human cells.

Authors:  Byong H Kang; Karin J Jensen; Jaime A Hatch; Kevin A Janes
Journal:  Sci Signal       Date:  2013-08-06       Impact factor: 8.192

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.